Riociguat
FDA-approved product (tablet, oral), marketed as Adempas, Riociguat.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Hypertension
- Idiopathic and/or familial pulmonary arterial hypertension
- Pulmonary arterial hypertension
- Pulmonary hypertension
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antihypertensives for pulmonary arterial hypertension
- FDA pharmacologic class
- Soluble Guanylate Cyclase Stimulator FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis68.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Riociguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Etrasimod ArginineExisting use: Ulcerative colitis64.1% AI-predicted activityagainst MRSANo documented evidence found
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more64.1% AI-predicted activityagainst MRSA50+ registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more63.6% AI-predicted activityagainst MRSA50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome63.6% AI-predicted activityagainst MRSA6 registered studies
- Nafarelin AcetateExisting use: Endometriosis63.6% AI-predicted activityagainst MRSA12 registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents63.6% AI-predicted activityagainst MRSA1 registered study
- Vinorelbine TartrateExisting use: Cancer, Neoplasm63.6% AI-predicted activityagainst MRSA50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis63.5% AI-predicted activityagainst MRSANo documented evidence found
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances63.4% AI-predicted activityagainst MRSA50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema63.4% AI-predicted activityagainst MRSA33 registered studies
- LonafarnibExisting use: Hutchinson-Gilford progeria syndrome, Laminopathies, Progeria63.3% AI-predicted activityagainst MRSA39 registered studies
- LypressinExisting use: Vasopressin and analogues63.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00810693 · start 2008-12-17
Registered record
- Registry ID
- NCT00810693
- Conditions
- Pulmonary Hypertension
- Interventions
- Riociguat (Adempas, BAY63-2521); Riociguat (Adempas, BAY63-2521); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-12-17
- Completion
- 2012-05-14
- Enrolment
- 445
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary HypertensionInterventionRiociguat (Adempas, BAY63-2521); Riociguat (Adempas, BAY63-2521); PlaceboPhasePhase 3Registry statusCompletedInteraction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID
NCT00680654 · start 2008-10
Registered record
- Registry ID
- NCT00680654
- Conditions
- Hypertension, Pulmonary
- Interventions
- Riociguat (Adempas, BAY63-2521)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2009-11
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension, PulmonaryInterventionRiociguat (Adempas, BAY63-2521)PhasePhase 1Registry statusCompletedImpact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
NCT00694850 · start 2008-08-02
Registered record
- Registry ID
- NCT00694850
- Conditions
- Hypertension, Pulmonary
- Interventions
- Riociguat (Adempas, BAY63-2521).
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-08-02
- Completion
- 2025-07-03
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension, PulmonaryInterventionRiociguat (Adempas, BAY63-2521).PhasePhase 2Registry statusCompletedCOMPERA / COMPERA-KIDS
NCT01347216 · start 2007-07-01
Registered record
- Registry ID
- NCT01347216
- Conditions
- Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2007-07-01
- Completion
- 2026-12-31
- Enrolment
- 14,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)InterventionNot recordedPhaseNot recordedRegistry statusRecruitingRiociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT01784562
Registered record
- Registry ID
- NCT01784562
- Conditions
- Hypertension, Pulmonary
- Interventions
- Adempas (Riociguat, BAY63-2521)
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- No longer available
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension, PulmonaryInterventionAdempas (Riociguat, BAY63-2521)PhaseNot recordedRegistry statusNo longer available